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Summary. The ability of the muscular carnitine pool to accept and temporally donate acetyl groups
(from and towards the coenzyme A pool) is an important functional role of carnitine within biological
systems that is often overlooked within the scientific literature. The present review will discuss recent
research demonstrating the existence of a period of inadequate acetyl-CoA delivery towards the tricar-
boxylic acid cycle (the so-called ‘acetyl group deficit’), which occurs as a consequence of the impaired
integration of cytosolic (glycolysis) and mitochondrial energy producing pathways at the onset of
muscular contraction; due to a lag in the activation of the pyruvate dehydrogenase complex. During
this period of inadequate acetyl-CoA delivery, acetyl groups can be sequestered from the limited
muscular acetylcarnitine reserve in an attempt to sustain continued tricarboxylic acid cycle flux. Fol-
lowing on from this, the present review will highlight the metabolic and functional benefits to be gained
by overcoming this period of metabolic inertia, through elevating the concentration of acetylcarnitine
prior to physical exercise; in the presence and absence of pyruvate dehydrogenase complex activation
and through appropriately timed ‘warm-up’ exercise.
Keywords. Pyruvate dehydrogenase complex; Acetylcarnitine; Metabolic inertia; Acetyl group
deficit; Oxidative metabolism.
Introduction
Carnitine, or 3-hydroxy-4-trimethylammonium butyrate, is a naturally occurring
compound ubiquitously found within mammalian tissues which marks the 100th
anniversary of its original discovery in skeletal muscle extracts this year [1]. L-
Carnitine, the biologically effective isomer of carnitine, plays a key role within
several cellular energy producing pathways [2]. By way of example, carnitine is
essential towards the transport of long-chain fatty acids across the inner-mitochon-
drial membrane towards their oxidative fate inside the mitochondrial matrix [3], is
 E-mail: PARoberts1975@Hotmail.com
important towards the removal of toxic acyl-CoAs from the mitochondria by form-
ing acylcarnitines [4, 5], serves as a temporal acetyl group buffer during the oxi-
dation of carbohydrates during periods of increased pathway flux [6, 7], and, in
accordance with the Hofmeister series, is an osmoprotectant [8]; thus can impact
upon cell volume and osmotic stress responses [9]. There is also expanding evi-
dence indicating that L-carnitine has more complex functions within the cell,
towards the regulation of gene expression [10, 11] and the blockage of apoptosis
at several stages [12–14]. This review article will focus on the physiological role
of the carnitine pool as an acceptor and temporal donator of acetyl groups (in the
form of acetyl-CoA) at the immediate onset of muscular contraction and will high-
light the beneficial effect of acetylating the carnitine pool prior to muscular con-
traction upon subsequent contractile performance.
Muscular Carnitine Pool and Fluctuations during Physical Exercise
A typical 70 kg omnivore male contains 21 g of carnitine, maintained through the
concerted actions of an active carnitine biosynthetic pathway in the kidney (30%
of daily requirement), efficient renal reuptake of carnitine from the urine, and from
the consumption of carnitine dense foods, i.e., red meats (70% of daily require-
ment) [15]. Skeletal muscle represents the major storage site of carnitine within the
body, accounting for90–95% of the total-carnitine reserve, with free-carnitine the
major constitute in resting tissue (80%), with the remainder made up of esterified
derivatives (acylcarnitines); products of reactions catalysed by carnitine acyltrans-
ferases (Fig. 1). Allied to the dominant distribution of carnitine towards the mus-
culature, there is also a biased distribution of carnitine within the cell, with 90%
of the carnitine pool existing outside of the mitochondria; possibly to aid the
carnitine mediated transport of activated long-chain acyl groups across the mito-
chondrial membranes [16, 17]. The intra and extra-mitochondrial carnitine stores
are linked by a reversible carnitine acetyltransferase (Fig. 1), which permits the
equilibration of mitochondrial derived acetyl groups with the larger cytosolic car-
nitine pool which can also lead to the acetylation of the limited cytosolic free-
coenzyme A pool [18–20].
The composition of the muscular carnitine pool alters acutely and chronically
in response to various external factors, ranging from diabetes [21], dietary compo-
sition [22], drug interventions [23], renal dialysis treatment [24], to physical exer-
cise [25]. Nowhere is this alteration more profound than during the transition from
rest to exercise where the concentration of acetylcarnitine can increase upto 5-fold
and account for 95% of the total-carnitine pool within the muscle [26]. Indeed,
during moderate to intense skeletal muscle contraction acetylcarnitine has been
shown to accumulate almost linearly with time [6, 25], with the rate of accumula-
tion being greater with increasing exercise intensity [26] and under conditions of
reduced blood flow (ischaemia) [27, 28] and oxygen availability (hypoxia) [29]. The
ability of free-carnitine to accept excess acetyl-CoA, when produced by the pyruvate
dehydrogenase complex in excess of the demands of the tricarboxylic acid cycle, is
critical given that the total store of free-coenzyme A within the muscle is relatively
small (50–60mol kg1 dry muscle) [30], with 95% of this store confined to
the mitochondria with the remainder existing extra-mitochondrially [31]. Indeed,
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without the creation of this reservoir of ‘active acetyl groups’ in the form of
acetylcarnitine, the increased flux through the pyruvate dehydrogenase complex
at the onset of contraction would acetylate the entire free-coenzyme A reserve
within just a few seconds, leading to the immediate cessation of flux through the
pyruvate dehydrogenase complex. The question arises as to why acetylcarnitine
accumulates, and more specifically why does acetyl-CoA (produced via the py-
ruvate dehydrogenase complex reaction) accumulate in excess of the requirements
of the tricarboxylic acid cycle? This lack of metabolic efficiency [32] could be
Fig. 1. Carnitine, the pyruvate dehydrogenase complex (PDC), and their location within the major
metabolic pathways; the PDC is depicted as a black-box in the centre of the diagram; Key: CAT¼
carnitine acetyltransferase; RCA¼ reversible carnitine acetyltransferase; MCC¼monocarboxylic
carrier; CPT1¼ carnitine palmitoyl-transferase 1; CPT2¼ carnitine palmitoyl-trasnferase 2; Tr¼
translocase; F1F0¼ F1F0 ATPase
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in part attributable to the evolutionary history of the mitochondria [33, 34], due to
carnitine acyltransferase competing more successfully for the available acetyl-CoA
than citrate synthase at the immediate onset of exercise or possibly exists as a
mechanism by which the energy demand of muscular contraction can be repaid
following exercise, when pyruvate dehydrogenase complex derived acetyl-CoA
delivery to the mitochondria is markedly reduced to preserve carbohydrate re-
serves. By way of example, following physical exertion the accumulated acetyl-
carnitine slowly declines back to its basal concentration as acetyl groups are
sequestered from this store to produce ATP and to replenish the phosphocreatine
store. Based on the almost linear increase in acetylcarnitine during exercise it has
been inferred that acetyl-CoA availability matches or is in excess of tricarboxylic
acid cycle requirements throughout contraction, although recent evidence has cast
doubt upon this inference [7]; a point I will return to later in the text.
Recently it has been observed that the concentration of acetylcarnitine can
decline during the first minute of contraction under conditions where the muscular
carnitine reserve had been near-maximally acetylated to acetylcarnitine through
pharmacological intervention [28]. This study raised, for the first time, the possi-
bility that if the availability of acetyl groups (in the form of acetylcarnitine or
acetyl-CoA) could be increased prior to muscular exertion, then this extra substrate
reserve could be utilised during subsequent contraction [28]. I will return to the
subject of acetylcarnitine utilisation during muscular contraction later in this
review.
Mitochondrial Energy Production at the Onset of Exercise –
‘The Oxygen Deficit’
At the onset of contraction a step-increase in the demand for free-energy, in the
form of ATP, is put in place by skeletal muscle. As the store of ATP within the cell
is limited (25 mmol kg1 dry muscle), pathways to regenerate ATP must be
rapidly activated to maintain both contractile function and cellular homeostasis.
It is a remarkable feature therefore that during contraction, at all but the highest of
intensities, the cellular concentration of ATP remains fairly constant. The increase
in demand for ATP cannot be met solely by oxygen-dependent ATP re-synthesis at
the onset of contraction, whose activation is delayed and follows an approximately
exponential time-course [35].
During this period of latency, the transient shortfall in mitochondrial-ATP pro-
duction, classically termed the ‘oxygen deficit’ [36, 37], is supplemented by ATP
re-synthesis from oxygen independent routes (i.e., ATP and phosphocreatine break-
down and lactate formation) [38–42]. By way of example, Bangsbo et al. [41]
observed that phosphocreatine hydrolysis and lactate accumulation collectively
contributed 80% of the total ATP generated during the initial 30 s of high-
intensity exercise. This figure declined to 45% from 60–90 s and to 30% after
120 s of exercise, and appeared to be accompanied by a parallel increase in mito-
chondrial ATP delivery. Although ATP production from oxygen-independent
routes enables rapid rates of ATP turnover to be achieved, it has only a finite ca-
pacity and also results in the accumulation of metabolic by-products that are dele-
terious to muscular contractile function (hydrogen ions, lactate ions, and inorganic
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phosphate) [43]. Indeed, without the progressive increase in mitochondrial ATP
production at the onset of contraction, and thereby the reduction in energy delivery
via oxygen-independent routes, the onset of muscular fatigue would be markedly
accelerated.
Classically, the lag in oxygen-dependent (mitochondrial) ATP re-synthesis at
the onset of contraction, and the resulting activation of oxygen-independent ATP
regeneration, has been attributed to an impaired rate of increase, or inertia, in
skeletal muscle blood flow and thereby oxygen delivery towards the contracting
muscle fibres [44–47]. Indeed, the temporal changes in muscle oxygen utilisation
at the onset of exercise closely follow the increase in total limb blood flow during
this period; hence the general acceptance of the phrase ‘oxygen deficit’ within the
literature [36, 37]. Over the past decade, however, there has been a growing body
of evidence indicating that neither muscle blood flow (bulk oxygen delivery) nor
capillary diffusion limit oxygen utilisation at the onset of exercise, such that the
true physiological genesis of the lag in oxidative ATP resynthesis remains open to
debate [35, 48, 49].
Metabolic Inertia – ‘The Acetyl Group Deficit’
Work by Grassi and colleagues investigating blood flow and oxygen uptake
kinetics at the onset of upright cycling exercise in humans noted an increase in
venous oxygen content during the first 15 s of contraction at a time when calculated
leg oxygen uptake was minimal, indicating that oxygen delivery was in excess of
oxygen demand at the very onset of contraction [50]. In a recent series of studies,
within an isolated and perfused canine gastrocnemius muscle model, Grassi and
co-workers demonstrated that elimination of the delay in oxygen delivery at the
onset of contraction, by keeping blood flow elevated did not affect the kinetics of
muscle oxygen consumption during sub-maximal contraction [51], but did result in
faster oxygen uptake by the muscle at a maximal exercise workload and a 25%
reduction in the calculated oxygen-deficit [52]. These findings suggest that mito-
chondrial ATP re-synthesis is not limited by convective blood flow, and thereby
oxygen delivery, during transitions from rest to sub-maximal workloads [51]. They
concluded that the limitations to the rate of increase in mitochondrial ATP re-
synthesis at the onset of exercise are likely attributable to heterogeneous micro-
vascular oxygen delivery and=or an intrinsic inertia within mitochondrial energy
production of unspecified origin.
Work within the laboratory of Prof. Paul Greenhaff (Nottingham, UK) over the
past decade has investigated the pyruvate dehydrogenase complex as a potential site
of limitation towards mitochondrial ATP re-synthesis at the immediate onset of
muscular contraction [7, 27, 28, 53–56]. The pyruvate dehydrogenase complex
(PDC) is a multi-enzyme complex, located on the mitochondrial inner membrane,
which regulates carbohydrate entry into the tricarboxylic acid cycle. The PDC ca-
talyses the physiologically irreversible reaction that commits carbohydrates to their
oxidative fate inside the mitochondria through the conversion of the glycolytic prod-
uct pyruvate into mitochondrial acetyl-CoA (involving NADþ and free-coenzyme
A as substrates, Fig. 2). Regulation of the rate of formation of acetyl-CoA by the
PDC (i.e., flux through the enzyme complex) is achieved by two strategies. The first
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of these is by altering the fraction of PDC that exists in its active form. This is
achieved by covalent modification of PDC, either from its inactive (phosphorylated)
to active (dephosphorylated) state by loosely associated pyruvate dehydrogenase
phosphatases, or vice versa by a number of intrinsic and tissue specific pyruvate
dehydrogenase kinases (Fig. 2) [57, 58]. These effectors of PDC activation are
sensitive to changes in calcium availability, cellular energetics, and substrate=
product accumulation [59, 60]. Secondly, the rate of pyruvate oxidation by PDC
is regulated by end-product inhibition of flux through the enzyme complex byNADH
and acetyl-CoA (Fig. 2) [57]. The acetyl groups produced by PDC can be utilised by
the tricarboxylic acid cycle or, alternatively, can be stockpiled in the form of ace-
tylcarnitine, presumably when acetyl-CoA re-synthesis exceeds its rate of utilisation
by citrate synthase [6]. Therefore, the muscular carnitine pool can be viewed as an
indirect stimulator of PDC flux (and thereby carbohydrate metabolism), through the
maintenance of a viable pool of free-coenzyme A for sustained tricarboxylic acid
cycle flux (Fig. 2).
In a landmark study by Timmons and co-workers in 1996 [53], pharmacological
activation of the PDC, using the systemic PDC kinase (PDK) inhibitor dichloro-
acetate (Fig. 2) [61, 62], markedly increased acetylcarnitine availability in resting
skeletal muscle and appreciably reduced phosphocreatine hydrolysis and lactate
accumulation during subsequent intense contraction and under conditions where
muscle blood flow and oxygen delivery were fixed at close to resting levels. Fol-
lowing on from this work, the Greenhaff group demonstrated in both canine and
human skeletal muscle that the rapid hydrolysis of phosphocreatine and accumula-
tion of lactate that occurs at the onset of exercise was at least partially due to an
inherent lag in the activation of oxygen-dependent (mitochondrial) ATP regenera-
tion [28, 54]. In particular, they were able to show that activation of the PDC at
rest, using dichloroacetate, was accompanied by 30% reduction in ATP re-syn-
thesis from oxygen-independent routes after 1 min of contraction, even though mus-
cle force production was identical to the saline treated (control) group. Following
Fig. 2. The pyruvate dehydrogenase complex reaction and covalent regulation of activation status by
the intrinsic pyruvate dehydrogenase phosphatase and kinase system; CoASH¼ free-coenzyme A;
Pi¼ inorganic phosphate; ()¼ an inhibitor of the enzyme it is beside; (þ)¼ an activator of the
enzyme it is beside; P¼ phosphorylation of the three specific serine residues upon the haloenzyme
core of the pyruvate dehydrogenase complex (PDC); Dichloroacetate¼ systemic pyruvate dehydro-
genase kinase inhibitor sodium dichloroacetate
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6 min of contraction, the contribution from oxygen-independent routes to ATP re-
synthesis had fallen to 50% of that observed in the control group, while tension
development was maintained much better [28]. It also appeared from these studies
that some of the acetyl groups that were stockpiled at rest after PDC activation
were utilised during contraction, indicating that the mitochondria were able to
utilise more acetyl groups at the onset of exercise when provision was increased
by dichloroacetate administration [28, 53]. From these investigations, it was con-
cluded that the activation, and thereby flux, through PDC must limit acetyl-CoA
availability and consequently mitochondrial ATP re-synthesis at the onset of exer-
cise. Moreover, that the activation of PDC and ‘priming’ of mitochondria with
acetyl groups prior to exercise, by administering dichloroacetate, could signifi-
cantly increase the overall contribution of oxidative pathways to total ATP produc-
tion at the onset of exercise. Another important finding from this series of studies
was that the decline in muscle tension development during contraction (i.e., fa-
tigue) was substantially reduced following dichloroacetate administration, most
probably due to phosphocreatine hydrolysis and lactate accumulation being re-
duced at the immediate onset of contraction [28, 53]. Furthermore, this effect
was sustainable throughout contraction, at least until the exercise workload was
increased to a near maximal intensity [54].
If inertia in the rate of increase in oxygen-dependant ATP regeneration at the
onset of exercise does indeed reside at the level of PDC, which the work of
Timmons et al. [28] certainly seems to indicate, then it stands to reason that a
period of time must exist at the onset of exercise when acetyl-CoA supply via
PDC is insufficient to match the demands of the tricarboxylic acid cycle, and the
concentration of acetyl-CoA should therefore decline. However, studies to date
have shown that acetyl groups appear to accumulate throughout moderate-to-
intense muscular contraction [6, 25, 27, 63]. From these findings, it has been
inferred that acetyl-CoA production is probably in excess of tricarboxylic acid
cycle demands throughout contraction, which contrasts with the generated hypoth-
esis that metabolic inertia resides at the level of PDC. Closer scrutiny of the
relevant literature reveals, however, that studies to date have failed to investigate
the metabolic events occurring within the initial seconds of contraction, or indeed,
at any time-point during contraction prior to significant PDC activation. Roberts
et al. comprehensively addressed this issue in 2002, in a study designed to con-
clusively address the issue of acetyl group availability at the immediate onset of
contraction [7]. Using a canine hind-limb perfusion model, five muscle biopsy
samples were obtained from the gracilis muscle during the first minute (rest, 10,
20, 40, and 60 s) of ischaemic muscle contraction, which was envisaged to give
sufficient resolution to elucidate the temporal relationship between PDC activation,
acetyl group accumulation, and phosphocreatine hydrolysis and lactate accumula-
tion at the onset of contraction [7]. The results demonstrated that a lag in acetyl
group provision (in the form of acetyl-CoA and acetylcarnitine) occurred during
the initial 20 s of contraction, which resulted from, and was mirrored by, a lag in
PDC activation (Control, Fig. 3). This unequivocally demonstrated the existence of
a period of metabolic inertia (the so called ‘acetyl group deficit’) in skeletal muscle
at the onset of contraction [7] and has been supported by further studies [56, 64].
Although the lag in acetyl-CoA and acetylcarnitine accumulation is only temporal
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and the numerical decline in their respective concentrations is only small, it is
important to recognise that the units on the y-axis of the acetylcarnitine graph
(Fig. 3C) are 1000-fold higher (mmol) than that of the acetyl-CoA (mol) graph
(Fig. 3B). Furthermore, it is important to recognise that 1 mmol of acetyl groups (in
the form of acetylcarnitine and acetyl-CoA) is stoichiometrically identical to
12 mmol of ATP equivalents being produced by the electron transport machinery;
in response to the entrance of a single acetyl-CoA moiety into the tricarboxylic
acid cycle and the generation of 1GTP, 3NADH, and 1FADH2 with each turn
of the cycle. So clearly, a small decline in acetylcarnitine concentration can have a
profound effect upon the amount of energy production required from the limited
oxygen independent routes.
As dichloroacetate activates the PDC and near maximally acetylates the free-
coenzyme A and carnitine pools at rest (Dichloroacetate, Fig. 3), it was not possible
to determine in any of our previous studies whether the reduction in oxygen-
independent ATP re-synthesis at the onset of contraction following dichloroacetate
treatment (Dichloroacetate, Fig. 4) was attributable to acetyl-CoA delivery via
the PDC being increased at the immediate onset of contraction (Dichloroacetate,
1
Fig. 3. Active form of the pyruvate dehydrogenase complex (PDCa) and acetyl-CoA and acetylcar-
nitine concentrations at rest and during 5 min of ischaemic contraction following pre-treatment with
control (open circles), sodium dichloroacetate (closed circles), and sodium acetate (closed triangles);
units are as follows: PDCa, mmol of acetyl-CoA min1 kg1 dry muscle (at 37C); acetyl-CoA,
mol kg1 dry muscle; acetylcarnitine, mmol kg1 dry muscle; results are expressed as means
SEM; significantly different from corresponding control value (p<0.05)
Fig. 4. Rates of ATP re-synthesis from oxygen independent routes (phosphocreatine and ATP degra-
dation and lactate accumulation) between rest and 1 min, 1 and 3 min, and 3 and 5 min of ischaemic
contraction following pre-treatment with control (white), sodium dichloroacetate (grey), and sodium
acetate (black); results are expressed as means SEM, with units of mmol of ATP equivalents
min1 kg1 dry muscle; significantly different from corresponding control value (p<0.05)
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Fig. 3A) and=or was due to the readily available pool of acetyl groups being seques-
tered by the tricarboxylic acid cycle (Dichloroacetate, Figs. 3B, 3C). With this
question in mind, we have recently investigated whether pharmacologically increas-
ing the availability of acetyl-CoA and acetylcarnitine, independent of PDC activa-
tion, could overcome the ‘acetyl group deficit’ at the onset of exercise [56]. We were
able to show that administration of sodium acetate increased the availability of
acetyl-CoA (Sodium acetate, Fig. 3B) and acetylcarnitine (Sodium acetate, Fig. 3C)
in resting skeletal muscle, but did not increase PDC activation (Sodium acetate,
Fig. 3A). Furthermore, during the first minute of ischaemic muscle contraction,
when the PDC was largely inactive (Sodium acetate, Fig. 3A), treatment with
sodium acetate increased the contribution of oxygen-dependent ATP regeneration
towards the energy demands of the muscle when compared to the saline treated
(control) group (Fig. 4) [56]. However, following this first minute, when near
maximal activation of PDC had been achieved in both control and acetate groups
(Fig. 3A), it appeared that PDC derived acetyl-CoA, rather than stockpiled acetyl
groups per se, was the principal route of substrate delivery to the tricarboxylic acid
cycle. Collectively these investigations have established the activation of the pyru-
vate dehydrogenase complex as a rate limiting step in the rate of rise in oxygen-
dependent ATP production in skeletal muscle at the onset of exercise, which in turn
will dictate the magnitude of oxygen-independent ATP delivery and thereby the rate
of fatigue development.
Warm-up Exercise and Carnitine
A period of low-intensity exercise, commonly referred to as ‘warm-up’ exercise, has
been shown to have a range of physiological and biochemical benefits upon perfor-
mance during a subsequent bout of exercise [65–68]. These benefits have been
classically attributed to exercise-induced elevations in muscle temperature and blood
(oxygen) delivery prior to the onset of a second bout of more intense exercise. As
stated previously, acetylcarnitine accumulates during muscular contraction before
gradually returning to its basal concentration upon the cessation of exercise; as the
accumulated acetyl groups are sequestered back towards the tricarboxylic acid cycle
(via the carnitine acyltransferase reaction, Fig. 1), to repay the energy cost of con-
traction (principally through PCr re-synthesis). Therefore, and in light of the findings
discussed above, a period of low-intensity (‘warm-up’) exercise, of sufficient dura-
tion to elevate muscular acetylcarnitine stores, could positively impact upon the rate
of onset of oxidative ATP re-synthesis and performance within a second bout of
more strenuous (prolonged) physical exercise, performed several minutes later. This
hypothesis was recently tested by Campbell-O’Sullivan et al. [55] where a group of
healthy male subjects performed 10 min of exercise at 75% maximal oxygen uptake
(VO2 max) in the presence and absence of 10 min of warm-up exercise (55% VO2
max), with a 3 min rest between bouts. Warm-up exercise elevated muscle acetylcar-
nitine by4 mmol kg1 dry muscle from basal prior to the start of the second bout of
exercise, independent of any alteration in resting blood flow, ATP, phosphocreatine,
and glycogen concentrations, and was associated with 40% reduction in the
requirement for oxygen-independent ATP re-synthesis [55]. Collectively these results
suggest that the ‘acetyl group deficit’ at the immediate onset of contraction can be
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overcome by appropriately timed warm-up exercise via an envisaged increased on-
set of mitochondrial ATP re-synthesis [55].
Conclusions and Future Perspectives
In conclusion, I hope the present review has provided convincing evidence to sup-
port the contention that pyruvate dehydrogenase complex activation, and thereby
acetyl-CoA availability, is limiting towards mitochondrial (oxidative) ATP re-
synthesis at the immediate onset of contraction, resulting in the sequestering of
acetyl groups from the limited mitochondrial acetylcarnitine reserve. Increasing
the concentration of acetylcarnitine prior to exercise, either directly (with sodium
acetate), via the activation and increased flux through the pyruvate dehydrogenase
complex (dichloroacetate), or through the performance of appropriately timed
‘warm-up’ exercise can overcome the ‘acetyl group deficit’ and accelerate the onset
of mitochondrial ATP re-synthesis. The consequences of this are a marked reduction
in ADP=AMP mediated phosphocreatine and glycogen degradation and lactate for-
mation resulting in a subsequent improvement in the maintenance of contractile
function. Based on this evidence, any strategy that can ‘prime’ the mitochondria or
increase their responsiveness towards a step-increase in energy demand upon the
initiation of muscular contraction, can be expected to be a novel therapeutic target
towards the treatment of clinical conditions where premature fatigue development
is prevalent; such as peripheral vascular disease.
In addition, it remains to be established if dietary L-carnitine supplementation
can elevate the muscular carnitine pool in man and thereby elevate the absolute
availability of acetylcarnitine prior to the onset of exercise. This desire is compli-
cated by the fact that the additional acetylcarnitine would need to be readily avail-
able towards the tricarboxylic acid cycle (i.e., predominantly located inside the
mitochondria) [32] and due to the difficulty in elevating the total-carnitine pool
(especially within skeletal muscle) through prolonged carnitine supplementation in
healthy (omnivore) humans [69]. Experiments targeted to address this issue will
need to wait until technological advancements in tissue specific and organelle
specific drug delivery systems have been perfected.
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